The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.
about
Insights into CYP2B6-mediated drug-drug interactionsCommon variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivoUnmet medical needs in lupus nephritis: solutions through evidence-based, personalized medicineCyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitisCytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for LymphomaCyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceGenetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic VariationHigh-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6.Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.Breath tests to phenotype drug disposition in oncology.The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients.High CYP2C19 phenotypic variability in gastrointestinal cancer patients.Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation.
P2860
Q28078857-99BC9D84-6061-4493-BC78-032EBE0D1947Q30418239-5ACCE487-EB1D-4830-BCB7-913801CF2079Q35647150-45087FEB-CFE4-4DCB-BB21-5AE65F31A8B6Q36088877-1F2306A8-71FC-4BCB-9048-AD8EFBFCF567Q36336024-1E85D2B6-69EA-4C15-80AF-B1C33DE7C11BQ36634466-94A64724-5EEF-42EE-865B-7369DEC97AAEQ36652629-CE0825C8-D0C7-44AE-9B39-68A26F9D110AQ36657589-09386FF0-D545-4C00-B706-7B2F59789FEBQ36802054-E241BBD5-2126-49F4-B0DA-B9AFE26C4500Q37062614-F99E1164-881E-4607-B187-270F968C769DQ37400962-BDA92D0E-28BD-441A-98B2-F80E25520F62Q37969220-49E1AFD9-B350-414E-B491-68FC9DA307A2Q38122635-FAC84CFD-21D4-4C85-8482-4B680CEBA5D7Q46250643-FBE4D04D-05EE-4BB8-8D4C-11BB54D8CE76Q48173698-1C50FC44-772A-4E91-BADD-C3CEA6F7739DQ49618000-167AFB59-CAB0-4C45-BBE9-28CAE33AB54CQ50271114-30C0003C-DEFD-4285-9C87-178AF9456FBAQ51144588-B1A32DF1-9F5D-4E07-8CF8-5802A8126E9CQ54686050-DD532CB9-FB27-4C01-90A9-7B52BE192393
P2860
The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The combined impact of CYP2C19 ...... yclophosphamide bioactivation.
@ast
The combined impact of CYP2C19 ...... yclophosphamide bioactivation.
@en
The combined impact of CYP2C19 ...... yclophosphamide bioactivation.
@nl
type
label
The combined impact of CYP2C19 ...... yclophosphamide bioactivation.
@ast
The combined impact of CYP2C19 ...... yclophosphamide bioactivation.
@en
The combined impact of CYP2C19 ...... yclophosphamide bioactivation.
@nl
prefLabel
The combined impact of CYP2C19 ...... yclophosphamide bioactivation.
@ast
The combined impact of CYP2C19 ...... yclophosphamide bioactivation.
@en
The combined impact of CYP2C19 ...... yclophosphamide bioactivation.
@nl
P2093
P2860
P50
P1476
The combined impact of CYP2C19 ...... yclophosphamide bioactivation.
@en
P2093
Chung-Yee Hui
Janak Z De Zoysa
Janet K Coller
Michael A Goldthorpe
Peter J Gow
P2860
P304
P356
10.1111/J.1365-2125.2010.03789.X
P407
P577
2010-12-01T00:00:00Z